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Summary. A saline feature of data from clinical trials and medical studies is inhomogeneity. Patients
not only differ in baseline characteristics, but also the way they respond to treatment. Optimal individu-
alized treatment regimes are developed to select effective treatments based on patient’s heterogeneity.
However, the optimal treatment regime might also vary for patients across different subgroups. In this
paper, we mainly consider patients heterogeneity caused by groupwise individualized treatment effects
assuming the same marginal treatment effects for all groups. We propose a new maximin-projection
learning for estimating a single treatment decision rule that works reliably for a group of future patients
from a possibly new subpopulation. Based on estimated optimal treatment regimes for all subgroups,
the proposed maximin treatment regime is obtained by solving a quadratically constrained linear pro-
gramming (QCLP) problem, which can be efficiently computed by interior-point methods. Consistency
and asymptotic normality of the estimator is established. Numerical examples show the reliability of the
proposed methodology.
Keywords: Heterogeneity; Maximin-projection learning; Optimal treatment regime; Quadratically
constrained linear programming.
1. Introduction
Data from clinical trials and medical studies are often characterized by some degree of inhomogene-
ity. Patients not only differ in baseline characteristics, but also the way they respond to the treat-
ment. There have been increasing interest in developing individualized optimal treatment regimes
(OTRs) to account for patients’ heterogeneity in response to treatment and to achieve the best treat-
ment effect for individual patients. Some common methods for estimating OTRs include Q-learning
(Watkins and Dayan, 1992; Chakraborty et al., 2010), A-learning (Robins et al., 2000; Murphy, 2003)
and value search methods which directly search OTRs by maximizing the estimated value function
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(Zhang et al., 2012; Zhao et al., 2012). However, the OTRs may also vary for patients from dif-
ferent subpopulations. This is typically the case in meta analysis, where we combine the results of
multiple studies conducted at different locations or times. One motivating example is from a multi
center randomised controlled trial as studied in Tarrier et al. (2004). The goal is to examine the
effectiveness of cognitive-behavioural therapy for patients with early schizophrenia. Patients can be
classified into three groups according to their treatment centres (Manchester, Liverpool and North
Nottinghamshire). As we can see in Section D in the supplementary article, the group-wise OTRs
can vary across different centres. Another example is from an observational study for investigating
the influence of early disease modifying antirheumatic drug (DMARD) treatment on patients with
recent onset inflammatory polyarthritis (Farragher et al., 2010). According to patients’ enrollment
time, they can be classified into three groups. As studied in Section 6, the group-wise OTRs can vary
across different enrollment periods. The heterogeneity in OTRs may be explained by the differences
in characteristics of treatment setting across subgroups. For instance, in the schizophrenia example,
the strength of therapeutic alliance between therapist and patient, the adherence to treatment proto-
cols and the quality of treatment provided can vary from one treatment centre to another (Dunn and
Bentall, 2007); in the inflammatory polyarthritis example, there are more use of hydroxychloroquine
for the methotrexate combination strategy in recruitment time group 3 (1997-2000) than in group 1
(1990-1992) or group 2 (1993-1996) as hydroxychloroquine was increasingly used in the UK before
anti-tumour necrosis factor therapy was introduced to treat rheumatoid arthritis in 2001. Moreover,
these characteristics are often unobserved or partially observed, and they may explain the interaction
between subgroups and OTRs.
The aim of this paper is to propose a reliable OTR for new patients based on the observed data from
different groups with heterogeneity in optimal treatment decision. The group of new patients may
differ from any of the currently observed groups in terms of optimal treatment decision. For example,
compared with existing data, the group of new patients, who come from a new treatment centre,
may have a different OTR because of different strength of therapeutic alliance or different quality
of treatment provided in the new treatment centre. Therefore, the true OTR for the group of new
patients is not estimable at all based on the observed data, and any of the group-wise OTRs may not be
the best choice. The challenge becomes how to derive a meaningful and reliable treatment regime that
can take into account the heterogeneity in optimal treatment decision for different groups of patients.
One simple approach is to pool the data of different groups together and obtain the “pooled” OTR
based on the pooled data. Another method is to first obtain the OTR for each group, and then
aggregate the group-wise OTRs in certain ways. Random effects meta-analysis (DerSimonian and
Laird, 1986) is commonly used to combine subject-specific studies. Using its multivariate extensions
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(cf. Jackson et al., 2010; Chen et al., 2012), we can aggregate the groupwise OTRs based on random
effects models. The resulting OTR is similar to the “pooled” OTR when we have large numbers of
subgroup patients. These OTRs maybe reasonable choices when the OTRs for different groups do not
vary much. However, when there is certain degree of heterogeneity in OTRs across different groups
as demonstrated in the toy example given in the next section, these OTRs are uniformly worse than
the proposed OTR for any of the groups. One possible reason is that these OTRs for different groups
may assign the same patient to different treatments and thus their effects are averaged out when
pooling the data from different groups.
Bu¨hlmann and Meinshausen (2016) and Meinshausen and Bu¨hlmann (2015) considered a maximin
criteria which has a nice characterization in linear models and proposed to use maximin aggregation
(magging) to obtain the maximin estimator. Their proposed estimator is shown to be more robust
than the pooled estimator in linear regression. The key idea of the maximin criteria is to find
an estimator that works the best under the worst-case scenario. In optimal treatment decision, the
percentage of making the correct decision (PCD) and value function are two commonly used measures
to evaluate the effectiveness of a treatment regime. A natural maximin criteria for optimal treatment
decision is to find an OTR that maximizes the minimum PCD or the minimum value function of all
groups. Such a maximin OTR is appealing due to its nice interpretation and robustness. However,
it is hard to implement in practice due to the following reasons. First, the PCD of a treatment
regime is generally not estimable from data since the true OTR is unknown. Second, the empirical
estimator of the value function as studied in Zhang et al. (2012) is non-smooth and non-concave, thus
the estimation of the associated maximin OTR is not feasible.
In this paper, we propose a novel maximin-projection learning (MPL) to aggregate linear OTRs
across different groups. Specifically, the proposed maximin-projection learning finds a linear decision
rule that maximizes the minimum “inner product” between the vectors of regression parameters in
the linear rule and the group-wise linear OTRs. We show that under certain model assumptions, the
OTR obtained by the maximin-projection learning maximizes the minimum percentage of making the
correct decision and value function of different groups, i.e. achieve the desired maximin properties. In
addition, the corresponding estimation procedure can be represented as a linear programming problem
with a quadratic constraint (Lee et al., 2016), which can be efficiently solved in O(Gs2 + s3) flops.
Here G denotes the number of groups and s the dimension of baseline covariates. Consistency and the
asymptotic distribution of the corresponding maximin-projection estimators are established. Such
kind of asymptotic results are rarely studied in the literature. To derive such asymptotic properties,
we establish a necessary and sufficient condition for the existence and uniqueness of the population
maximin-projection parameters and obtain a closed-form expression for the resulting estimator.
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The rest of the paper is organized as follows. We introduce the model, notations and assumptions
in Section 2. We also provide a heuristic comparison between the maximin OTR, the pooled OTR
and the OTR based on random effects models with a toy example. In Section 3, we formally intro-
duce the proposed maximin-projection learning including its statistical interpretation and geometrical
characterization. Section 4 presents the estimating procedure of the maximin-projection estimator
and the associated asymptotic properties. Simulation studies to evaluate the empirical performance
of the proposed maximin OTR are conducted in Section 5. We apply our method to a real examples
in Section 6, followed by a Conclusion Section. Proof of theorem 2 is provided in Section A. Other
proofs and additional numerical studies are given in the supplementary article.
2. Preliminaries and a toy example
2.1. Preliminaries
For simplicity, we consider a single stage study with two treatments. Let Y denote a patient’s response
of interest, the larger the better by convention, A ∈ A = {0, 1} the treatment received by the patient
and X the associated s-dimensional vector of baseline covariates. In addition, let Y ∗(0) and Y ∗(1)
denote the potential outcomes that a patient would get if he or she was given treatment 0 and 1,
respectively. A treatment regime d is a deterministic function that maps a patient’s covariates to
{0, 1}. Define the potential outcome
Y ∗(d) = Y ∗(1)d(X) + Y ∗(0){1− d(X)},
representing the response that a patient would get if treated according to the regime d. The optimal
treatment regime is defined as the regime dopt that maximizes E{Y ∗(d)}. Under the stable unit
treatment value assumption (SUTVA) and no unmeasured confounders assumption (Rubin, 1974),
the optimal treatment regime can be written as dopt(x) = I{C(x) > 0} where
C(x) = E(Y |A = 1, X = x)− E(Y |A = 0, X = x).
Function C(·) is referred to as the contrast function. In practice, for simplicity, we may assume
the contrast takes a linear form, i.e, C(x) = βTx+ c. To take population heterogeneity into account,
we assume that the contrast function varies for patients from different groups. Specifically, we assume
there are G groups of patients and consider the following semiparametric model:
Yg = hg(Xg) +Ag(β
T
g Xg + cg) + eg, g = 1, . . . , G. (1)
where E(eg|Xg, Ag) = 0. In Model (1), Yg, Ag and Xg ∈ Rs stand for the response, the treatment
and the covariates of patients in Group g, respectively, and hg denotes the unspecified baseline func-
tion in Group g. Without loss of generality, we further assume all covariates Xg are standardized
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to have zero mean and identity covariance matrix. Otherwise, we consider variable transformation
X∗g = Σ
−1/2
g (Xg − µg), β∗g = Σ1/2βg, c∗g = cg + µTg βg where µg = E(Xg) and Σg = cov(Xg). Then
Model (1) can be represented as Yg = h
∗
g(X
∗
g ) +Ag(β
∗
g
TX∗g + c
∗
g) + eg, for some function h
∗
g. The pa-
rameter cg stands for the marginal treatment effects (average causal effects) after adjusting covariates.
Mathematically, we have
cg = E{Y ∗g (1)} − E{Y ∗g (0)}.
When cg > 0, treatment 1 is generally better for patients in Group g. The vector βg describes
individualized treatment effects. For patients in Group g with covariates x, the larger βTg x, the more
benefits he or she receives if assigned to treatment 1.
Define pig(x) = Pr(Ag = 1|Xg = x) as the propensity score in Group g. Model (1) allows hg and
pig to vary across groups, which we refer to baseline effect heterogeneity and treatment assignment
heterogeneity respectively. These sources of heterogeneity are not related to treatment decisions since
they do not appear in the contrast function. The following sources of groupwise heterogeneity will
affect decision making: the marginal treatment effects cg and the individualized treatment effects βg.
In this paper, we mainly focus on heterogeneity caused by different βg’s. We assume c1 = · · · = cG =
c0 for some c0, that is, the same marginal treatment effect for all groups.
To introduce the pooled and the maximin optimal treatment regime, we need some optimality
criterion. Here, we consider the difference of patient’s mean response (value function) between a
regime d(x) = I(βTx > −c) and d0(x) = 0, which assigns all patients to treatment 0. Specifically,
the difference of value functions is defined as
VDg(β, c) = E{Y ∗g (d)} − E{Y ∗g (d0)} = E{(XTg βg + c0)I(XTg β > −c)}.
In this section, for illustrative purposes only, we consider a special case with c0 = c = 0. A general
discussion will be given in the next section. When the distributions of Xgs are the same across groups,
we can represent VDg(β, 0) as
VD(β, βg) = E{(XTg βg)I(XTg β > 0)}.
We assume the same number of patients across all groups. Then, the pooled optimal treatment regime
is defined as doptP (x) = I(x
TβP > 0) where
βP = arg max
∥β∥2=1
1
G
G∑
g=1
VD(β, βg), (2)
and the maximin optimal treatment regime is defined as doptM (x) = I(x
TβM > 0) where
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
VD(β, βg). (3)
6 C. Shi, R. Song, W. Lu and B. Fu
We add the L2 constraint on β to make β
P and βM identifiable. Therefore, the pooled optimal
treatment regime aims to maximize the average value difference while the maximin optimal treatment
regime aims to maximize the minimum value difference in G groups, i.e. maximize the reward of the
worst-case scenario.
The random effects meta-analyses assume the following model for βg’s:
βg = β0 + εg,
where εg’s are independent and satisfy E(εg) = 0, cov(εg) = Ω0 for all g. For any subgroup estimators
βˆ1, . . . , βˆG with cov(βˆg) = Ωg, the aggregated estimator is given by
βˆR =

 G∑
g=1
(Ωˆg + Ωˆ0)
−1


−1
 G∑
g=1
(Ωˆg + Ωˆ0)
−1βˆg

 ,
where Ωˆg’s and Ωˆ0 denote some estimators for Ωg’s and Ω0. Given sufficiently many observations, we
have ∥βˆg − βg∥2 P→ 0 and ∥Ωˆg∥2 P→ 0. As a result, we have
βˆR
P→

 G∑
g=1
(Ωˆ0)
−1


−1
 G∑
g=1
(Ωˆ0)
−1βg

 = 1
G
∑
g
βg ≡ βR. (4)
The corresponding optimal treatment regime is defined as doptR (x) = I(x
TβR > 0).
More generally, we can treat the parameters βg in the group-specific contrast function as a mul-
tivariate random variable and assume that the parameters βg’s of training groups are generated
according to some distribution Fb, either continuous or discrete, and let Hb denote the support of Fb.
Then, we define βR, βP and βM as
βR = Etrain,b(b),
βP = arg max
∥β∥2=1
Etrain,b{VD(β, b)},
βM = arg max
∥β∥2=1
min
b∈Hb
VD(β, b),
where the expectation Etrain,b is taken with respect to Fb. Definitions in (2), (3) and (4) correspond to
the special case where Fb only takes values in {β1, . . . , βG} with an equal probability. Our objective
is to minimize Etest,b{VD(β, b)}, where Etest,b is taken with respect to Gb, the distribution of βg for
future groups of patients.
2.2. A toy example
Recall that s is the dimension ofXg. For illustration, we take s = 2, and assume that patients’ baseline
covariates are generated independently from a standard normal distribution. Since ∥β∥2 = 1, after
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some calculation, we have
VD(β, βg) = E{XTg βgI(XTg β > 0)} = E{(XTg βg − βTg βXTg β + βTg βXTg β)I(XTg β > 0)}
= βTg βE
{
XTg βI(X
T
g β > 0)
}
= βTg β
1√
2pi
.
The first equality in the second line is due to the independence between XTg βg − βTg βXTg β and
XTg β. Hence, we obtain
βP = arg max
∥β∥2=1
1
G
G∑
g=1
βTβg =
∑
g βg
∥∑g βg∥2 ,
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
βTβg. (5)
Therefore, βP is proportional to βR which equals a simple average of all subgroup parameters,
while βM maximizes its minimum inner product across different βg’s. When all βg’s have the same
L2 norm, β
M becomes
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
βTβg
∥βg∥2 , (6)
or equivalently
βM = arg min
∥β∥2=1
max
g∈{1,...,G}
∠(β, βg), (7)
where ∠(a, b) = arccos(aT b) stands for the angle between two vectors. The equivalence between
(6) and (7) is due to the monotonicity of the arccos function. In (6) or (7), βM is defined to
maximize (minimize) the minimum correlation (maximum angle) between all subgroup coefficients.
Such formulation is referred to as the maximin correlation approach in the classification literature
(c.f, Avi-Itzhak et al., 1995; Lee et al., 2016). In general, we weight the correlation βTβg/∥βg∥2 by the
L2 norm of βg. The β
M defined in (5) is more informative since it not only takes the heterogeneity
due to different directions βg/∥βg∥2 into consideration, but different magnitudes ∥βg∥2 as well.
Since βP is proportional to βR, the VD under doptP is the same as d
opt
R . Therefore, in the following,
we focus on comparing βP with βM . We set G = 4 and assume ∥βg∥2 = 1, g = 1, 2, 3, 4. Since s = 2,
we represent each βg as βg = {cos(ψg), sin(ψg)} with ψg ∈ [0, pi). The parameter ψg is the angle
between βg and the x-axis in a 2-dimensional coordinate system. In this special case, β
M lies on the
bisector of the largest angles formed by all βg’s and it can be shown that β
M = {cos(ψM ), sin(ψM )}
where
ψM =
1
2
(
ψ(1) + ψ(4)
)
,
ψ(1) and ψ(4) denote the smallest and largest angles of ψg’s. Similarly define β
P = {cos(ψP ), sin(ψP )}.
We set ψ1 = 0
◦, ψ2 = 15
◦, ψ3 = 70
◦ and ψ4 = 90
◦. Consider the following leave-one-group-out cross
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validation procedure. For the ith round, we choose the ith group as the testing group, and obtain
βP and βM based on the remaining 3 groups. Then we evaluate the value difference of the pooled
and maximin OTRs based on the ith group. In other words, we set Fb to be a discrete distribution
that takes value on {β1, . . . , β4}/{βi} with equal probability, and Gb a degenerate distribution that
concentrates on βi. Table 1 summarizes the results.
Table 1: Different combinations of training groups and the corresponding ψP , ψM , and their value differences
on the testing group
Training groups ψM (deg) ψP (deg) ψtest (deg) VD(β
M , βtest) VD(β
P , βtest)
(1, 2, 3) 35 27.44 90 0.23 0.18
(1, 2, 4) 45 32.63 70 0.36 0.32
(1, 3, 4) 45 55.32 15 0.35 0.30
(2, 3, 4) 52.5 59.25 0 0.24 0.20
From Table 1, we can see that for all four cases, the value differences of the maximin optimal
treatment regime are uniformly larger than those of the pooled optimal treatment regime on the
testing groups. To illustrate the idea graphically, we plot βP (denoted by the snow symbol), βM
(denoted by the circle symbol), and βg of the training (denoted by the square symbol) and testing
(denoted by the plus symbol) groups for the second and third cases in Figure 1, where the left panel
is for the second case and the right one is for the third case. For both cases, βM is closer to βg of the
testing groups, while βP is pulled towards the area where most βg’s of the training groups locate due
to the averaging effect.
Fig. 1: Plots of βP (denoted by the snow symbol), βM (denoted by the circle symbol), and βg of the training
(denoted by the square symbol) and testing groups (denoted by the plus symbol) for the second (left panel)
and third (right panel) cases.
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3. Maximin-projection learning
We now formally introduce our maximin projection treatment regime. Based on model (1) and the
common marginal treatment effect assumption, the optimal treatment regime for the gth subgroup
is doptg (x) = I(xTβg > −c0). Here, our goal is to find a single treatment regime doptM (x) = I(xTβM >
−cM ) with ∥βM∥2 = 1 that performs uniformly well for heterogeneous data. Motivated by the toy
example in the previous section, our proposed maximin-projection learning is aim to find
βM = arg max
β:∥β∥2=1
min
g∈{1,...,G}
βTβg.
3.1. Statistical interpretation
In this subsection, we show that the maximin projection, represented by βM , has two nice statistical
interpretations in terms of maximizing the minimum PCD and value difference (VD). Specifically, in
group g, the PCD of a treatment regime d(x) = I(xTβ > −c) is defined as
PCDg(β, c) = 1− E
{|I(XTg β > −c)− I(XTg βg > −c0)|} ,
and the VD is defined as
VDg(β, c) = E[Y
∗
g {I(XTg β > −c)}]− E{Y ∗g (0)} = E
{
(XTg βg + c0)I(X
T
g β > −c)
}
.
Here, the larger PCD and VD values, the better the treatment regime d(x) approximates the groupwise
optimal treatment regime doptg (x).
Based on the defined PCD and VD, for any fixed constant c, we consider the following maximin
treatment regimes: d1(x) = I(x
TβM(1) > −c) where
βM(1) = arg max
β:∥β∥2=1
min
g∈{1,...,G}
PCDg(β, c), (8)
and d2(x) = I(x
TβM(2) > −c) where
βM(2) = arg max
β:∥β∥2=1
min
g∈{1,...,G}
VDg(β, c). (9)
Remark 3.1. The two maximin treatment regimes, defined by βM(1) and β
M
(2), are appealing for
their nice statistical interpretations. However, we note that the definition of βM(1) involves unknown
parameters. The empirical estimators of VD are of non-smooth and non-concave functional forms
of the corresponding estimators. Therefore, their estimations are not feasible and they may not be
practically useful.
Remark 3.2. It is worth noting that βM(1) would be meaningless when not all ∥βg∥2’s are the same.
This is because PCD only measures the similarity between the overall and groupwise optimal treatment
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decisions, but does not account for the magnitude of groupwise contrast function. When ∥βg∥2’s are
not the same, the L2 norm of groupwise contrast function {E(XTg βg + c0)2}1/2 would be different.
This implies that PCDs are not comparable across different groups. In comparison, VD is a better
criterion since it takes both the sign and magnitude of contrast function into consideration. Below,
under some conditions, we establish the equivalence between these two maximin treatment regimes
and our proposed maximin-projection treatment regime.
Theorem 1 (Equivalence of βM and βM(1)). Assume that Xg’s are i.i.d. spherically distributed,
and all ∥βg∥2’s are the same. Then, for any fixed c,
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
PCDg(β, c).
Theorem 2 (Equivalence of βM and βM(2)). Assume Xg’s are i.i.d. spherically distributed.
Then, for any fixed c,
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
VDg(β, c).
Remark 3.3. Theorems 1 and 2 require Xg to have a spherical distribution (see Definition F.1),
which is a rich class of symmetric multivariate distributions (see Fang et al., 1990).
The definition of βM has nice statistical interpretations. However, it has two drawbacks. First,
when F0 ≡ max∥β∥2=1ming βTβg < 0, the uniqueness of βM is not guaranteed. This may cause
identifiability issues when we establish properties of the corresponding estimators. In addition, the
optimization problem in (5) is not concave. This can make the implementation of the estimating
procedure infeasible.
To address these concerns, we define
βM(0) = arg max
∥β∥2≤1
min
g∈{1,...,G}
βTβg. (10)
Compared to βM , it replaces the feasible set ∥β∥2 = 1 with a closed convex set ∥β∥2 ≤ 1. Lemma
1 below states that βM(0) is well defined, when F0 ̸= 0. Moreover, the optimization problem (10) is
concave, which can be easily implemented.
Lemma 1. The maximin-projection estimator βM(0) always exists. Moreover, when F0 ̸= 0, βM(0) is
unique.
Remark 3.4. The existence of βM(0) is guaranteed by the continuity of the objective function F (β) =
ming∈{1,...,G} β
Tβg, boundedness and closeness of the feasible set β : ∥β∥2 ≤ 1. Its uniqueness is a
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byproduct of lemma 3, which is stated in the next subsection. When F0 = 0, β
M
(0) is not unique and
the set of solutions is given by
{aβ : a ∈ [0, 1], ∥β∥2 = 1, max
∥β∥2=1
min
g∈{1,...,G}
βTβg = 0}.
The problem of estimating βM(0) then becomes non-regular and all the large sample theories about the
maximin estimator fail (see Section 4).
Define G0 = max∥β∥2≤1ming β
Tβg. It is obvious that G0 ≥ 0. In addition, G0 > 0 if and only if
F0 > 0. When G0 = 0, we can set β
M
(0) = 0, which leads to a trivial regime by assigning the same
treatment to all patients. From now on, we focus on the situation when G0 > 0. In this case, we
have βM = βM(0). Define
cM(0) = c0/G0.
Note that cM(0) and c0 are sign equivalent. Our maximin-projection OTR is given by
doptM (x) = I(x
TβM(0) > −cM(0)).
Theorem 3. Under conditions of theorem 1, if G0 > 0, we have
cM(0) = argmaxc
min
g∈{1,...,G}
PCDg(β
M
(0), c).
Theorem 4. Under conditions of theorem 2, if G0 > 0, we have
cM(0) = argmaxc
min
g∈{1,...,G}
VDg(β
M
(0), c).
Together with theorems 1 and 2, theorems 3 and 4 suggest that the treatment regime doptM (x)
maximizes the minimum PCD and the minimum VD among different groups.
3.2. Geometrical characterization
In this subsection we give a geometrical view of βM(0) when G0 > 0. Findings in this subsection are
similar in rationale with the results in Avi-Itzhak et al. (1995). However, we generalize their results
by getting rid of the unit L2-norm condition ∥βg∥2 = 1 and allowing the set of vectors {β1, . . . , βG}
to be linear dependent, which is the case when s ≥ G.
We first introduce some notation. For an arbitrary s×G matrix Ψ and a set K ⊆ {1, . . . , G}, let
ΨK denote the submatrice of Ψ formed by columns in K. Define the equicorrelated points set
EK(Ψ) =
{
t ∈ Rs|tTΨj = tTΨi, ∀i, j ∈ K
}
,
and the optimal equicorrelated point
E⋆K(Ψ) = arg max
t∈EK(Ψ)
∥t∥2=1
{
tTΨi, ∀i ∈ K
}
,
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where Ψi refers to the ith column vector of matrix Ψ. When |K| = 1 and ΨK = ψ, E⋆K(Ψ) =
ψ/∥ψ∥2. Readers can refer to Section B of the supplementary article for a detailed discussion on the
equicorrelated points set and the optimal equicorrelated point.
For any matrix Ω, Let Ω+ denote the Moore-Penrose matrix inverse of Ω and C(Ω) the column
space of Ω. Let e denote a vector of ones. We have the following result.
Lemma 2. For any Ψ and K ⊆ [1, . . . , n], when e ∈ C(ΨTK), the optimal equicorrelated point of
ΨK exists and is unique. Moreover, it takes the form
E⋆K(Ψ) = [e
T (ΨTKΨK)
+e]−1/2ΨK(Ψ
T
KΨK)
+e. (11)
Define matrix B = (β1, β2, . . . , βG) whose gth column is the subgroup parameter βg.
Lemma 3. Assume G0 > 0. Then there exists a unique nonempty set K0 ⊆ [1, . . . , G] such that
βM(0) = E
⋆
K0(B) and ming∈Kc0 β
M
(0)
T
βg > G0, where K
c
0 = [1, . . . , G]−K0. Moreover, if the set of vectors
βg, g ∈ K0 are linearly independent, then a necessary and sufficient condition for βM(0) = E⋆K0(B) is
that each element in the vector (BTK0BK0)
−1e is nonnegative.
We denote K0 as the maximin optimal equicorrelated points set when G0 > 0. In lemma 2, the
condition e ∈ C(ΨTK) automatically holds when ΨTK has full row rank. In lemma 3, we assume the
set of vectors βg, g ∈ K0 are linearly independent. This implies the matrix BTK0 has full row rank. As
a result, we have e ∈ C(BTK0).
In lemma 3, the non-negativity of (BTK0BK0)
−1e is sufficient and necessary for βM(0) = EK0(B).
Together with lemma 2, lemma 3 implies that βM(0) is uniquely defined by
βM(0) = E
⋆
K0(B) = [e
T (BTK0BK0)
−1e]−1/2BK0(B
T
K0BK0)
−1e.
This implies E⋆K0(B) is proportional to BK0(B
T
K0
BK0)
−1e and can be represented as a linear com-
bination of the column vectors in BK0 . Geometrically, the non-negativity of (B
T
K0
BK0)
−1e requires
E⋆K0(B) to lie in the convex cone of βg, g ∈ K0, i.e, {
∑
g∈K0
agβg : ag ≥ 0, ∀g ∈ K0}. To better
understand lemma 3, in Figure 2, we take s = 3, G = 3 and B = (β1, β2, β3) where β1 = (1, 1, 0),
β2 = (1,−1, 0) and β3 = (1.2, 0, 0.5). Both E⋆{1,2,3}(B) and E⋆{1,2}(B) satisfy the necessary conditions
of lemma 3. While E⋆{1,2}(B) lies in the convex cone of β1 and β2, E
⋆
{1,2,3}(B) appears outside the
convex cone of β1, β2 and β3. Therefore, E
⋆
{1,2}(B) satisfies the sufficient conditions of lemma 3 and
E⋆{1,2,3}(B) doesn’t. As a result, we have β
M
(0) = E
⋆
{1,2}(B).
4. Estimation procedure
The data are summarized as (Ygj , Agj , Xgj), for g = 1, . . . , G, j = 1, . . . ,mg, wheremg is the number of
patients in Group g. We assume that the data are independent across g = 1, . . . , G and j = 1, . . . ,mg.
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Fig. 2: Plots of βg (denoted by the square symbol), E
⋆
{1,2,3}(B) (denoted by the snow symbol) and E
⋆
{1,2}(B)
(denoted by the circle symbol)
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Based on the data, parameters β1, . . . , βG and c0 in model (1) can be estimated with existing methods.
In this paper, we implement with the popular Q-learning and A-learning and give a brief discussion
on estimating these parameters in Section 4.2. Let βˆ1, . . . , βˆG and cˆ0 be the corresponding estimators.
We propose to estimate βM(0) by solving the following optimization problem:
βˆM = arg max
β:∥β∥2≤1
min
g∈{1,...,G}
βT βˆg. (12)
Note that the objective function ming β
T βˆg is concave in β and the region ∥β∥2 ≤ 1 is convex.
Therefore, (12) is a tractable convex optimization problem. It can be further casted as a quadratic
constraint linear programming (QCLP) problem, specifically, βˆM is equivalent to the solution of
maximize t ∈ R
subject to βT βˆg ≥ t, g = 1, . . . , G
βTβ ≤ 1.
The above optimization problem can be efficiently computed using existing softwares. Define cˆM =
cˆ0/Gˆ0, where Gˆ0 = ming βˆ
T
g βˆ
M .
Given a group of future patients, denoted by {XG+1,j}nj=1 their baseline covariates. We calculate
µˆG+1 =
∑n
j=1XG+1,j/n and ΣˆG+1 =
∑n
j=1(XG+1,j−µˆG+1)(XG+1,j−µˆG+1)T /(n−1). The recommend
treatment for the jth patient is given by
I{(XG+1,j − µˆG+1)T Σˆ−1/2G+1 βˆM > −cˆM}.
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4.1. Statistical properties
In this subsection we investigate the asymptotic properties of the maximin-projection estimator βˆM
obtained by solving the optimization problem (12). We first study the consistency of the estimator
by assuming the following two conditions.
(C1.) Assume that βˆ1, . . . , βˆG and cˆ0 converge in probability to β1, . . . , βG and c0, respectively.
(C2.) Assume that F0 ̸= 0. When F0 > 0, assume that the column vectors in BK0 are linearly
independent and all elements in the vector (BTK0BK0)
−1e are nonzero, where K0 is the maximin
optimal equicorrelated points set as defined previously.
Remark 4.1. Condition (C1) requires each subgroup estimator to be consistent. The condition
F0 ̸= 0 in (C2) ensures the existence and uniqueness of βM(0). Apparently, βM(0) is not stable when F0
approaches to 0, since its L2 norm will change from 1 to 0. To ensure the stability of β
M
(0) in the sense
that it will not deviate too much when there are minor changes in the set of vectors β1, . . . , βG, we
would expect
∥[B˜TK0B˜K0 ]+ − [BTK0BK0 ]+∥2 → 0, (13)
as B˜K0 → BK0 , where B˜ = (β˜1, . . . , β˜G) represents the coefficient matrix with some disturbance. A
sufficient condition to establish (13) is that BK0 is of full column rank, as assumed in Condition
(C2). Lemma 2 suggests βM(0) can be represented as ω
T
0 BK0, for some weight vector ω0 proportional to
(BTK0BK0)
−1e. Condition (C2) further assumes the weights are nonzero. Such a condition guarantees
that for any coefficient matrix B˜ → B, K0 is the optimal equicorrelated points set of B˜ as well.
Theorem 5 (Consistency). Define Bˆ = (βˆ1, . . . , βˆG). Assume Conditions C1 and C2 are sat-
isfied. Then with probability tending to 1, the estimator βˆM is equal to

{eT (BˆTK0BˆK0)−1e}−1/2BˆK0(BˆTK0BˆK0)−1e if F0 > 0,
0 if F0 < 0.
In addition, assume there exist some r
(1)
n , r
(2)
n → 0 such that maxg∈K0 ∥βˆg − βg∥2 = Op(r(1)n ) and
cˆ0 = c0 +Op(r
(2)
n ). When F0 > 0, we have ∥βˆM − βM(0)∥2 = Op(r
(1)
n ), cˆM = cM(0) +Op(r
(1)
n + r
(2)
n ).
Remark 4.2. Theorem 5 implies that (βˆM , cˆM ) is consistent as long as each subgroup estimator
is consistent. The first part of the theorem follows as a consequence of lemma 3.
Next, we study the asymptotic normality of the estimator. For notational simplicity, we assume
m1 = · · · = mG = m and posit the following condition.
(C3.) Assume that for all g ∈ K0,
√
m(βˆg − βg) and
√
m(cˆ0 − c0) are jointly asymptotically normal
with mean zero.
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Theorem 6 (Asymptotic normality). Assume that Conditions C1–C3 hold, and that F0 > 0.
We have that
√
m(βˆM − βM(0)) and
√
m(cˆM − cM(0)) are jointly asymptotically normal with mean zero
and some covariance matrix VM . The expression of VM is given in Appendix C.
Since the expression of the asymptotic covariance matrix VM is quite complicated, we propose to
estimate it using a bootstrap method. Here, the bootstrap sampling is done within each subgroup.
Specifically, we independently generate B bootstrap samples for each group g = 1, . . . , G,
{
(Y
(j)
g1 , A
(j)
g1 , X
(j)
g1 ), . . . , (Y
(j)
gm , A
(j)
gm, X
(j)
gm)
}
,
j = 1, . . . , B. For each j, we obtain estimators βˆ(j) and cˆ(j) based on the data
{
(Y
(j)
11 , A
(j)
11 , X
(j)
11 ), . . . , (Y
(j)
1m , A
(j)
1m, X
(j)
1m)
}
, . . . ,
{
(Y
(j)
G1 , A
(j)
G1, X
(j)
G1), . . . , (Y
(j)
Gm, A
(j)
Gm, X
(j)
Gm)
}
.
Confidence intervals of βˆM and cˆM are calculated based on quantiles of (βˆ(1), . . . , βˆ(B)) and (cˆ(1), . . . , cˆ(M)).
4.2. Estimation of group-specific regimes
In this subsection we discuss two popular approaches to obtain subgroup estimators βˆg and cˆ0.
Example 1 (Q-learning). We estimate βg and c0 by modeling the Q-functions, which represent
the conditional mean of the response given the covariates and the treatment. Specifically, the baseline
function is assumed to have some parametric form hg(x, ηg) with parameter ηg. Then,
Qg(Xg, Ag;βg, c0, ηg) ≡ E(Yg|Ag, Xg) = hg(Xg, ηg) +Ag(XTg βg + c0), g = 1, . . . , G.
Since c0 is common across all subgroups, we propose to estimate β1, . . . , βG and c0 by jointly solving
the following set of estimating equations:
∑
j
∂hg(Xgj , ηg)
∂ηg
{Ygj −Qg(Xgj , Agj ;βg, c0, θg)} = 0, g = 1, . . . , G,
∑
j
AgjXgj{Ygj −Qg(Xgj , Agj ;βg, c0, θg)} = 0, g = 1, . . . , G,
∑
g
∑
j
Agj{Ygj −Qg(Xgj , Agj ;βg, c0, θg)} = 0.
When the parametric models hg(x, ηg)’s are correctly specified, the resulting estimators βˆg’s and cˆ0
are consistent and jointly asymptotically normal.
Example 2 (A-learning). Here, we posit some parametric model pig(X,αg) for the propensity
score and hg(X, ηg) for the baseline function. The parameters αg’s, ηg’s, βg’s and c0 are estimated
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by solving the following set of estimating equations:
∑
j
1
pig(X,αg){1− pig(X,αg)}
∂pig(X,αg)
∂αg
{Agj − pig(X,αg)} = 0, g = 1, . . . , G,
∑
j
∂hg(Xgj , ηg)
∂ηg
{Ygj − hg(Xgj , ηg)−Agj(XTgjβg + c0)} = 0, g = 1, . . . , G,
∑
j
Xgj{Agj − pig(Xgj , αg)}{Ygj − hg(Xgj , ηg)−Agj(XTgjβg + c0)} = 0, g = 1, . . . , G,
∑
g
∑
j
{Agj − pig(Xgj , αg)}{Ygj − hg(Xgj , ηg)−Agj(XTgjβg + c0)} = 0.
It can be shown that when either the propensity score or the baseline function for each group is correctly
specified, the resulting estimators βˆg’s and cˆ0 are consistent and jointly asymptotically normal. This
is the so-called doubly robust property of the A-learning estimation.
5. Simulation studies
We consider four groups of patients. In each group, we generate 200 samples according to the following
model
Ygj = h(Xgj) +AgjX
T
gjβg + εgj ,
where Xgj = (X
(1)
gj , X
(2)
gj )
T iid∼ N(0, I2) and εgj iid∼ N(0, 0.25). Two baseline models are considered
for h, including a linear model h(Xgj) = 1 + 0.5X
(1)
gj + 0.5X
(2)
gj and a nonlinear model h(Xgj) =
1 + sin(0.5piX
(1)
gj + 0.5piX
(2)
gj ). We generate treatments from two propensity score models, a constant
model, Pr(Agj = 1) = 0.5 and a probit model, Pr(Agj = 1|Xgj) = Φ(X(1)gj −X(2)gj ), where Φ(·) is the
standard normal cumulative distribution function. This yields four simulation settings.
We further consider two scenarios for the subgroup parameters to exhibit different degrees of het-
erogeneity. In the first scenario, we set βT1 = (2, 0), β
T
2 = (2 cos(15
◦), 2 sin(15◦)), βT3 = (2 cos(70
◦), 2 sin(70◦)),
βT4 = (0, 2). Hence, all βg’s have the same L2 norm and their directions βg/∥βg∥2 differ. For
the second scenario, we choose subgroup parameters to have similar directions but allow their L2
norms to vary. Specifically, βT1 = (2.2 cos(30
◦), 2.2 sin(30◦)), βT2 = (1.5 cos(45
◦), 1.5 sin(45◦)), βT3 =
(2.2 cos(54◦), 2.2 sin(54◦)), βT4 = (2 cos(60
◦), 2 sin(60◦)). It can be shown that βM(0) = (cos(45
◦), sin(45◦))
and cM(0) = 0 for all scenarios.
We first obtain the subgroup estimators of βg and c0 using the A-learning estimating equations
discussed in Section 4.2. Here, a logistic regression model is fitted for the propensity score and a
linear model for the baseline function. As a result, both the propensity score model and the baseline
model are correctly specified in the first setting; either of them is misspecified in the second and the
third setting; while both are misspecified in the last setting. We then obtain the estimators βˆM and
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cˆM using the proposed maximin-projection learning. Confidence intervals for the resulting estimators
are obtained based on 600 bootstrap samples.
Table 2: Biases, standard deviations (in parenthesis) of βˆM , cˆM and coverage probabilities (CP) of 95%
Wald-type confidence intervals for βM(0) and c
M
(0).
Scenario 1 βˆM1 βˆ
M
2 cˆ
M CP for βˆM1 CP for βˆ
M
2 CP for cˆ
M
Setting 1 −0.002(0.027) 0.001(0.027) 0.0003(0.024) 96.0% 96.0% 95.3%
Setting 2 −0.003(0.053) −0.001(0.052) 0.001(0.045) 94.7% 94.7% 93.8%
Setting 3 −0.003(0.036) 0.001(0.035) −0.0005(0.035) 96.2% 96.2% 94.5%
Setting 4 −0.003(0.068) −0.004(0.068) 0.002(0.068) 96.0% 96.0% 95.0%
Scenario 2 βˆM1 βˆ
M
2 cˆ
M CP for βˆM1 CP for βˆ
M
2 CP for cˆ
M
Setting 1 −0.002(0.036) 0.0002(0.036) 0.0002(0.023) 95.5% 95.5% 95.3%
Setting 2 −0.009(0.061) 0.003(0.060) −0.001(0.043) 96.0% 96.0% 93.8%
Setting 3 −0.010(0.091) −0.002(0.089) −0.001(0.033) 93.7% 93.7% 94.5%
Setting 4 −0.029(0.136) 0.034(0.130) −0.002(0.056) 98.3% 98.3% 95.0%
For each setting, we conduct 600 simulations. The biases, standard deviations (SD) of βˆM and cˆM ,
and coverage probabilities (CP) of 95% Wald-type confidence intervals for βM(0) and c
M
(0) are reported in
Tables 2. In all scenarios, the proposed estimators achieve the smallest biases and standard deviations
in Setting 1, where the baseline function and the propensity score are both correctly specified. In
Settings 2 and 3, the proposed estimators are nearly unbiased, showing the doubly robust property
of the subgroup estimators obtained using the A-learning estimating equations. In Setting 4, where
the baseline function and the propensity score are both misspecified, biases and standard deviations
of the estimators tend to be larger, however, the biases are still reasonably small. In addition, the
coverage probabilities of 95% Wald-type confidence intervals are close to the nominal level for all
cases.
To further assess the performance of the proposed maximin OTRs, we compare it with the es-
timated pooled OTR, dˆP (x) = I(xT βˆP > −cˆP ) and the OTR based on random effects models,
dˆR(x) = I(xT βˆR > −cˆR). Here, βˆP and cˆP are obtained based on pooled data by solving a single
A-learning estimating equation. To obtain βˆR and cˆR, we first obtain βˆg, cˆg by solving A-learning
estimating equations, based on {Xgj , Agj , Ygj}mj=1. The covariance of (βˆTg , cˆg)T is estimated by the
sandwich estimator. Based on these estimators, we calculate βˆR and cˆR using the R package mvmeta.
The between-group covariance matrix is estimated by the method of moments. For both scenarios, we
consider the following leave-one-group-out cross-validation procedure for evaluation. We first obtain
estimators βˆM , cˆM , βˆP , cˆP , βˆR and cˆR based on pooled samples of any three groups. Then, we
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evaluate the PCD and the VD as defined in Section 3.1 under the obtained maximin OTR and the
pooled OTR for the remaining testing group, using Monte Carlo simulations based on the true model
for the testing group.
Table 3 and 4 summarize the results of the VD for Scenario 1 and Scenario 2. The results of the
PCD are given in Table 21 and 22 in the supplementary article. The OTR obtained by random effects
meta-analyses is close to the estimated pooled OTR in both scenarios. In Scenario 1, both the PCD
and the VD under our maximin OTR are much higher than those under the other two OTRs for all
the testing groups. Taking PCD as an example, on average, the PCD under the maximin OTR is
approximately 5 ∼ 6% higher than those under the other OTRs. This demonstrates the advantages
of the proposed maximin-projection learning when there is relatively large heterogeneity in optimal
treatment decision-making across subgroups. In Scenario 2, since the groupwise optimal treatment
regimes are “close” to each other in “angles”, all the estimated OTRs do not differ much. From Table
4, it can be seen that our maximin OTR performs better than the other OTRs when the first group
is taken as the testing group, while it has comparable performance with the other OTRs for other
groups as testing groups.
In Section C.2 in the supplementary article, we conduct some additional simulation experiments
with non-normal covariates. Findings are similar to those with normal covariates.
Table 3: VD results (with standard errors in parenthesis) for Scenario 1 under the estimated maximin OTR
dˆM , the pooled OTR dˆP and the OTR obtained by random effects meta-analyses dˆR.
Testing group First group Second group Third group Fourth group
Setting 1
dˆP 0.407(0.002) 0.606(0.001) 0.632(0.002) 0.368(0.002)
dˆR 0.408(0.001) 0.608(0.001) 0.633(0.001) 0.367(0.001)
dˆM 0.486(0.001) 0.690(0.001) 0.723(0.001) 0.458(0.001)
Setting 2
dˆP 0.406(0.002) 0.606(0.002) 0.630(0.002) 0.366(0.002)
dˆR 0.407(0.001) 0.608(0.001) 0.633(0.001) 0.366(0.001)
dˆM 0.483(0.002) 0.689(0.001) 0.719(0.001) 0.452(0.002)
Setting 3
dˆP 0.407(0.003) 0.604(0.002) 0.630(0.002) 0.367(0.003)
dˆR 0.405(0.002) 0.606(0.001) 0.632(0.001) 0.367(0.002)
dˆM 0.483(0.002) 0.688(0.001) 0.723(0.001) 0.454(0.002)
Setting 4
dˆP 0.406(0.003) 0.602(0.003) 0.628(0.003) 0.365(0.003)
dˆR 0.406(0.002) 0.606(0.001) 0.632(0.001) 0.366(0.002)
dˆM 0.473(0.003) 0.686(0.002) 0.716(0.001) 0.439(0.004)
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Table 4: VD results (with standard errors in parenthesis) for Scenario 2 under the estimated maximin OTR
dˆM , the pooled OTR dˆP and the OTR obtained by random effects meta-analyses dˆR.
Testing group First group Second group Third group Fourth group
Setting 1
dˆP 0.803(<0.001) 0.597(<0.001) 0.865(<0.001) 0.762(<0.001)
dˆR 0.803(<0.001) 0.598(<0.001) 0.865(<0.001) 0.761(<0.001)
dˆM 0.847(<0.001) 0.588(<0.001) 0.865(<0.001) 0.769(<0.001)
Setting 2
dˆP 0.802(0.001) 0.597(<0.001) 0.864(<0.001) 0.761(<0.001)
dˆR 0.803(<0.001) 0.598(<0.001) 0.865(<0.001) 0.762(<0.001)
dˆM 0.843(0.001) 0.587(<0.001) 0.863(<0.001) 0.767(0.001)
Setting 3
dˆP 0.801(0.001) 0.597(<0.001) 0.863(<0.001) 0.760(0.001)
dˆR 0.801(0.001) 0.597(<0.001) 0.864(<0.001) 0.761(0.001)
dˆM 0.841(0.001) 0.588(<0.001) 0.861(0.001) 0.765(0.001)
Setting 4
dˆP 0.799(0.001) 0.595(<0.001) 0.861(0.001) 0.758(0.001)
dˆR 0.804(0.001) 0.597(<0.001) 0.863(<0.001) 0.759(0.001)
dˆM 0.826(0.002) 0.587(0.001) 0.853(0.001) 0.756(0.002)
Although our maximin estimators have better performance for treatment decision making in the
above simulation examples, they can have larger variances compared with the random effects models.
This is a potential disadvantage of our method.
6. Health assessment questionnaire progression data
The health assessment questionnaire progression data comes from an observational study to investi-
gate the influence of early disease modifying antirheumatic drug (DMARD) treatment and its duration
for patients with recent onset inflammatory polyarthritis (Farragher et al., 2010). Early DMARDs
treatment was routinely used in the management of rheumatoid arthritis (RA). Among conventional
DMARDs, Methotrexate is the most widely used one and is now considered a benchmark against
new treatments to be used. Previous studies showed that RA patients who have failed to respond
to methotrexate may have clinically important improvements if treated with combination DMARDs,
such as methotrexate-sulfasalazine-hydroxychloroquine, methotrexate-sulfasalazine-steroids or other
Methotrexate combinations (Boers et al., 1997). However, Methotrexate combinations did not work
for all RA patients, and they may not add benefits in some patients who were stable on DMARD
monotherapy (Symmons et al., 2005). It is of clinical interest to develop individualized OTRs and to
know which patients will benefit from treating with Methotrexate combinations. The study sample
include 420 patients who were recruited to the study from 1990 to 2000 and were treated with either
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methotrexate monotherapy or methotrexate combinations. Age, gender, duration of disease, HAQ
score, number of swollen joints and number of tender joints were recorded at baseline. We standard-
ize all six covariates such that their sample covariance matrix equals the identity matrix within each
group. We compare methotrexate combinations (A = 1) with methotrexate monotherapy (A = 0).
The difference HAQ scores between baseline and 5-year is set to be the response. Here, we classify 420
patients into three groups according to their recruitment time. Specifically, group 1 includes patients
enrolled from 1990 to 1992; group 2 includes those enrolled from 1993 to 1996; and group 3 includes
those enrolled from 1997 to 2000. Sample sizes of the three groups are 265, 78 and 77, respectively.
In our analysis, we use the last two standardized covariates to fit the contrast function, since the
regression coefficients of other variables are not significant. Denoted these two covariates by X
(1)
gj and
X
(2)
gj , respectively. For each group g, we consider the following model
E(Ygj |Xgj , Agj) = hg(Xgj) +Agj(c0 + βg1X(1)gj + βg2X(2)gj ).
The parameters c0, βg1, βg2 are estimated using the A-learning estimating equations as discussed
in Section 4.2. Here, a linear model is fitted for the baseline function and a logistic regression
model is fitted for the propensity score. When fitting the propensity score model, all six covariates
are included. Table 5 reports the group-wise estimators obtained using the A-learning estimating
equations, suggesting there is some heterogeneity in optimal treatment regimens across three groups.
Table 5: Estimators of groupwise OTR (standard errors in paranthesis) for the HAQ data.
Group 1 Group 2 Group 3
βˆg1 0.05(0.11) −0.40(0.17) 0.07(0.21)
βˆg2 0.07(0.11) 0.06(0.21) 0.32(0.16)
Table 6: dˆM , dˆP , dˆR and their value functions
Testing group Group 1 Group 2 Group 3
dˆM dˆP dˆR dˆM dˆP dˆR dˆM dˆP dˆR
cˆ −0.87 −0.14 −0.12 −2.38 −0.21 −0.11 −3.08 −0.31 −0.32
βˆ1 −0.48 −0.02 −0.00 0.61 0.16 0.16 −0.02 0.06 −0.01
βˆ2 0.88 0.25 0.23 0.79 0.10 0.14 1.00 0.06 0.10
EˆY ⋆g (d) −0.08 −0.09 −0.09 −0.09 −0.19 −0.22 −0.12 −0.13 −0.12
We use the same leave-one-group-out cross validation procedure as done in simulations to evaluate
the performance of the proposed method. We calculate the maximin OTR dˆM , the pooled OTR dˆP ,
and the OTR obtained by random effects meta-analyses dˆR based on every two groups of patients, and
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evaluate them on the remaining group based on the estimated value function. For a given treatment
regime d and group g, the estimated value function is given by
EˆY ⋆g (d) =
1
mg
mg∑
j=1
[
Ygj +
(
cˆ0 + βˆg1X
(1)
gj + βˆg2X
(2)
gj
)
{d(Xgj)−Agj}
]
,
which is computed based on the advantage function as introduced in Murphy (2003). Results are
given in Table 6. Value under the maximin OTR are uniformly better than those under other OTRs
across all three groups, showing a big improvement for group 2. Besides, the estimators involved in
the regimes dˆP and dˆR are very close.
7. Discussion
In this paper, we propose a maximin-projection learning to aggregate OTRs for patients from different
populations with heterogeneity. It has appealing statistical interpretations in the sense of maximizing
the minimum PCD and the minimum value difference across subgroups. The corresponding estimation
procedure is easy to implement via quadratically constrained linear programming, and the asymptotic
properties of the resulting estimators are studied.
7.1. Alternative maximin formulation
Our procedure requires to scale the baseline covariatesXg to mean zero and identity covariance matrix
for g = 1, 2, . . . , G,G+ 1. Let Xg,0 be the original variable prior to transformation and βg,0, cg,0 the
corresponding individualized and marginal treatment effects, respectively. The proposed maximin
OTR is constructed based on βM = argmax∥β∥2=1ming∈{1,...,G} β
Tβg, or equivalently,
βM∗ = arg max
∥Σ
1/2
G+1β∥2=1
min
g∈{1,...,G}
βTΣ
1/2
G+1Σ
1/2
g βg,0,
where Σg is the covariance matrix of Xg,0 for g = 1, . . . , G+ 1.
As pointed by one of the referee, we can also consider the maximin OTR based on βM∗∗ where
βM∗∗ = arg max
∥Σ
1/2
G+1β∥2=1
min
g∈{1,...,G}
βTΣG+1βg,0.
Assuming EX1,0 = EX2,0 = · · · = EXG,0 = EXG+1,0 = 0, c1,0 = c2,0 = · · · = cG,0 and XG+1 is
spherically distributed, we can show
βM∗∗ = arg max
∥Σ
1/2
G+1β∥2=1
min
g∈{1,...,G}
E(XTG+1,0βg,0 + cg,0)I(X
T
G+1,0β + c),
for any c > 0. This implies that βM∗∗ maximizes the minimum groupwise value difference function
under the new distribution XG+1,0.
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It is worthwhile to investigate the performance of the OTR based on βM∗∗. However, this is
beyond the scope of the current paper. Below, we briefly compare the proposed maximin OTR
with the maximin OTR based on βM∗∗ and discuss their connections. First, βM∗∗ maximizes the
minimum groupwise value difference function under the new distribution XG+1,0 while β
M maximizes
the minimum groupwise value difference function under the new distribution XG+1 after scaling. To
see this, note that when c1 = · · · = cG and XG+1 is spherically distributed, we have
βM = arg max
∥β∥2=1
min
g∈{1,...,G}
E(XTG+1βg + cg)I(X
T
G+1β + c),
for any c > 0. Second, βM∗∗ usually doesn’t coincide with βM∗. A sufficient condition for βM∗ = βM∗∗
is that Σ1 = Σ2 = · · · = ΣG = ΣG+1. Lastly, estimating βM∗∗ might exhibit less variances than βM∗,
since it doesn’t require the estimation of Σ1, . . . ,ΣG. However, the OTR based on β
M∗∗ is not scale
invariant. To see this, let X∗∗G+1 = CXG+1,0 for some invertible matrix C. The covariance matrix of
XG+1,0 is equal to CΣG+1C
T . Let
βM∗∗∗ = arg max
∥Σ
1/2
G+1C
Tβ∥2=1
min
g∈1,...,G
βTCΣG+1C
Tβg,0,
there’s no guarantee that βM∗∗∗ = (CT )−1βM∗∗.
7.2. Extensions
In current work, we mainly deal with heterogeneity caused by groupwise individualized treatment
effects βg’s, and assume the same marginal treatment effects cg for all groups. It is possible to extend
our proposed maximin projection learning to the case when cg’s vary across different groups as well.
Specifically, consider
(βˆM , cˆM ) = arg max
∥β∥22+c
2≤1
min
g∈{1,...,G}
(
βˆTg β + cˆgc
)
,
where βˆg and cˆg are subgroup estimators. Statistical properties of βˆ
M and cˆM can be similarly
established. For example, βˆM and cˆM can be shown to converge almost surely to some βM(0) and
cM(0), respectively. However, the defined β
M
(0) and c
M
(0) can no longer preserve the interpretation of
maximizing the minimum PCD and the minimum VD, due to the fact that the PCD and the VD
are complicated functions of (βg, cg) and (β, c) when cgs vary across groups. Consequently, the angle
interpretation as demonstrated by the toy example given in Section 2.2 does not hold.
To establish the consistency and asymptotic normality of βˆM and cˆM , we require βg, g ∈ K0 to
be linearly independent. In Section C.1 in the supplementary article, we conduct some additional
simulation studies to examine our methods under settings where some of the βg’s are the same.
Results suggest that βˆM and cˆM are still consistent to βM(0) and c
M
(0), in these settings. We further
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evaluate the VD and the PCD under the estimated maximin OTR and compare them with those
under the estimated pooled OTR. Findings are similar to those in Section 5.
In addition, in our current work, we assume a linear interaction between treatment and baseline
covariates. It is interesting to consider a more general model as follows:
Yg = hg(Xg) +AgQ(β
T
g Xg + cg) + eg, g = 1, . . . , G, (14)
where Q is a strictly monotone increasing function with Q(0) = 0. The parameters βg in each group
can be consistently estimated using the concordance-assisted learning method by Fan et al. (2017).
The properties of the corresponding maximin-projection estimator warrant further investigation.
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A. Proof of theorem 2
Before proving theorem 2, we state the following lemma whose proof is given in Section F of the
on-line supplementary article.
Lemma 4. Consider a set of vectors β1, . . . , βG of dimension s and function h(β, b, t) defined on
the domain
{
(βT , bT , t) ∈ Rs × Rs × T : ∥β∥2 = 1
}
. Assume h(β, b, t) = g(βT b, t) for some function
g(·, ·). Besides, assume for any fixed t, g(c, t) is monotonically increasing as a function of c. Then,
for any random variable T defined on T , we have
arg max
β∈Rp
∥β∥2=1
min
g
Eh(βg, β, T ) = arg max
β∈Rp
∥β∥2=1
min
g
βg
Tβ.
Since Xg’s are identically distributed for g = 1, . . . , G, we omit the subscript g for brevity. We need
to show βM maximizes
min
g
[
E
{
hg(X) + (X
Tβg + c0)I(X
Tβ > −c)}− Ehg(X)] = min
g
E(XTβg + c0)I(X
Tβ > −c).
We first show for any ∥β∥2 = 1 and c, the probability Pr(XTβ > c) is constant as a function of β.
Since ∥βg∥2 = 1, it follows from lemma F.1 that there exists some orthogonal matrix U such that
Uβ = e1 = (1, 0, . . . , 0)
T . Hence
Pr(XTβ > c) = Pr(XTUTUβ > c) = Pr(XTUT e1 > c) = Pr(X
T e1 > c), (15)
where the last equality is due to the definition of spherical distribution (see Definition F.1). By (15),
it suffices to show βM maximizes
min
g
E(XTβg)I(X
Tβ > −c). (16)
Let ρg = β
Tβg/∥βg∥2. Since X is spherically distributed, we have
E(XTβg)I(X
Tβ > −c) = ∥βg∥2E
(
ρgX
(1) +
√
1− ρ2gX(2)
)
I
(
X(1) > −c
)
, (17)
for all βg, c and β such that ∥β∥2 = 1, where X(1) and X(2) are the first two components of the
random vector X. It follows from theorem 2.6 in Fang et al. (1990) that
(X(1), X(2))
d
= rd(U1, U2), (18)
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with r = ∥X∥2, d ∼ B(1, p/2 − 1), U1 and U2 uniformly distributed on the surface u21 + u22 = 1,
where B(p, q) stands for the Beta distribution with parameters p, q. The random variables r, d are
independent of U1 and U2. Set T = rd. Combining (17) with (18) gives
E(XTβg)I(X
Tβ > −c) = E∥βg∥2T (ρgU1 +
√
1− ρ2gU2)I(TU1 > −c) (19)
= E
[{
E∥βg∥2t(ρgU1 +
√
1− ρ2gU2)I(U1 > −c/t)
}
|T = t
]
≡ E[h(β, βg, t)|T = t],
for any β and c such that ∥β∥2 = 1.
When c/t ≤ −1, we have I(U1 > −c/t) = I(U1 > 1) = 0 and hence h = 0. When c/t ≥ 1,
h(β, βg, t) = t∥βg∥2E(ρgU1 +
√
1− ρ2gU2) = 0.
Obviously, in these two trivial cases, h is an increasing function of βTβg. Now we consider the case
where c/t = cos(ψ1) for some ψ1 ∈ (0, pi). Assume ρg = cos(ψ2) for some ψ2 ∈ (0, pi). The function h
can further be simplified to
h(β, βg, t) =
1
2pi
∫ ψ1
−ψ1
∥βg∥2t{cos(ψ2) cos(ψ) + sin(ψ2) sin(ψ)}dψ
=
1
2pi
t∥βg∥2
∫ ψ1
−ψ1
cos(ψ − ψ2)dψ = 1
pi
t∥βg∥2 sin(ψ1) cos(ψ2) = 1
pi
t sin(ψ1)β
Tβg.
This proves h is an increasing function of βTβg. Hence, (16) follows by an application of lemma 4.
